Ad
CARA Quote Trading Chart Cara Therapeutics Inc.
home / stock / cara / cara quote
$11.76 Last:
29.23% Change Percent:
$11.46 Open:
$9.10 Previous Close:
$11.85 High:
$11.4 Low:
64,945 Volume:
12/31/1969 07:00:00 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
CARA Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2022-08-15 | 11.46 | 9.1 | 11.85 | 11.4 | 64,945 |
| 2022-08-12 | 11.72 | 9.1 | 11.8 | 11.31 | 352,056 |
| 2022-08-11 | 12.54 | 9.1 | 12.98 | 11.55 | 933,913 |
| 2022-08-10 | 11.98 | 9.1 | 12.78 | 11.68 | 819,654 |
| 2022-08-09 | 11.5 | 9.1 | 12.2899 | 11.48 | 943,467 |
| 2022-08-08 | 11.03 | 9.1 | 11.65 | 10.9239 | 615,043 |
| 2022-08-05 | 10.39 | 9.1 | 11.31 | 10.18 | 652,398 |
| 2022-08-04 | 9.4 | 9.1 | 10.44 | 9.4 | 572,978 |
| 2022-08-03 | 8.83 | 9.1 | 9.5 | 8.83 | 406,156 |
| 2022-08-02 | 8.25 | 9.1 | 9.01 | 8.2456 | 610,211 |
| 2022-08-01 | 8.86 | 9.1 | 8.86 | 8.13 | 929,566 |
| 2022-07-29 | 9 | 9.1 | 9.035 | 8.66 | 390,819 |
| 2022-07-28 | 9.1 | 9.1 | 9.19 | 8.87 | 295,128 |
| 2022-07-26 | 9.12 | 9.12 | 9.345 | 8.66 | 204,822 |
| 2022-07-25 | 9.83 | 9.06 | 9.83 | 9.01 | 287,959 |
| 2022-07-19 | 9.2 | 9.63 | 9.78 | 9.2 | 460,608 |
| 2022-07-18 | 9.43 | 9.18 | 9.71 | 9.14 | 394,430 |
| 2022-07-15 | 9.37 | 9.25 | 9.37 | 8.93 | 323,368 |
| 2022-07-14 | 9.58 | 9.2 | 9.65 | 9.09 | 316,986 |
| 2022-07-13 | 9.19 | 9.61 | 9.78 | 9.19 | 266,129 |
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
Ad
-
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
-
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
-
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...